HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH SEVERE ASTHMA TREATED WITH TEZEPELUMAB IN SPAIN. INSIGHT FROM THE T-ROSS II STUDY
Author(s)
Laura Contreras, Mrs1, Francisco Ramos-Lima, Dr2, Marta Robles, Dr2, Marta Alegría Llorente, Mrs2, Gema Monteagudo, Dr2, Javier Dominguez, Dr3, CHRISTIAN Domingo, Dr.4.
1AstraZeneca Farmacéutica Spain, S.A., Madrid, Spain, 2Biopharmaceutical Medical, AstraZeneca Farmacéutica Spain, S.A., Madrid, Spain, 3Allergology Service, Hospital Universitario La Paz, Madrid, Spain, 4Pneumology Service, Hopsital Universitario Parc Taulí, Sabadell, Spain.
1AstraZeneca Farmacéutica Spain, S.A., Madrid, Spain, 2Biopharmaceutical Medical, AstraZeneca Farmacéutica Spain, S.A., Madrid, Spain, 3Allergology Service, Hospital Universitario La Paz, Madrid, Spain, 4Pneumology Service, Hopsital Universitario Parc Taulí, Sabadell, Spain.
OBJECTIVES: Patients with severe asthma (SA) often require substantial healthcare resource utilization (HCRU), generating high direct costs and environmental burden. Although tezepelumab has demonstrated clinical benefit in severe uncontrolled asthma (SUA) in clinical trials, data from routine clinical practice in Spain and its effect on healthcare utilization, costs, and related greenhouse gas emissions are still scarce.The objective is to evaluate the impact of initiating treatment with tezepelumab on HCRU, and associated costs in patients with SUA in Spain.
METHODS: The T-ROSS II was a retrospective, observational, multicenter study including patients with SUA treated with tezepelumab in Spain (recruited between June and December 2025). The analysis included data on emergency room (ER) admissions, hospitalizations, ICU admissions, primary care (PC), and specialist visits, across two time periods: 12 months before and 12 months after tezepelumab initiation. Greenhouse gas (GHG) emission modelled factors per HCRU were applied to estimate environmental impact. Costs and emissions were based on relevant published literature from the Spanish National Health System perspective.
RESULTS: A total of 420 patients were included, 71.19% females with a mean (SD) age of 56.99 (13.92). After the initiation of treatment with tezepelumab, it was observed a decrease in the number of asthma related visits, especially in emergency visits (43.96%) and unscheduled hospitalizations (33.33%), resulting in a reduction of 21.82% in healthcare costs with annual savings of €438,948.78 per 1,000 patients (€438.99 per patient), excluding drug cost. These reductions in HCRU resulted in an estimated decrease of 23,659 kg CO₂eq emissions per 1,000 patients (equivalent to 72 round-trip flights between Madrid and Vienna).
CONCLUSIONS: Patients with SUA treated with tezepelumab had reductions in the number of hospitalizations, costs, and carbon emissions, suggesting that better disease control may drive both better clinical outcomes and greater environmental sustainability, which reinforce the value of optimizing severe asthma management.
METHODS: The T-ROSS II was a retrospective, observational, multicenter study including patients with SUA treated with tezepelumab in Spain (recruited between June and December 2025). The analysis included data on emergency room (ER) admissions, hospitalizations, ICU admissions, primary care (PC), and specialist visits, across two time periods: 12 months before and 12 months after tezepelumab initiation. Greenhouse gas (GHG) emission modelled factors per HCRU were applied to estimate environmental impact. Costs and emissions were based on relevant published literature from the Spanish National Health System perspective.
RESULTS: A total of 420 patients were included, 71.19% females with a mean (SD) age of 56.99 (13.92). After the initiation of treatment with tezepelumab, it was observed a decrease in the number of asthma related visits, especially in emergency visits (43.96%) and unscheduled hospitalizations (33.33%), resulting in a reduction of 21.82% in healthcare costs with annual savings of €438,948.78 per 1,000 patients (€438.99 per patient), excluding drug cost. These reductions in HCRU resulted in an estimated decrease of 23,659 kg CO₂eq emissions per 1,000 patients (equivalent to 72 round-trip flights between Madrid and Vienna).
CONCLUSIONS: Patients with SUA treated with tezepelumab had reductions in the number of hospitalizations, costs, and carbon emissions, suggesting that better disease control may drive both better clinical outcomes and greater environmental sustainability, which reinforce the value of optimizing severe asthma management.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE259
Topic
Economic Evaluation, Study Approaches
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)